8-K: Impact BioMedical Completes 1-for-12.62 Reverse Stock Split

Impact BioMedical Inc. has officially executed a 1-for-12.62 reverse stock split, adjusting its issued and outstanding common stock, with trading on a split-adjusted basis commencing September 23, 2026.

Summary

• Impact BioMedical Inc. has completed a 1-for-12.62 reverse stock split of its common stock.
• The reverse stock split was approved by the Board of Directors on November 24, 2025, and by stockholders on December 30, 2025.
• The Certificate of Amendment was filed with the Secretary of State of Nevada on September 23, 2026, and became effective at 12:01 A.M. EST on the same date.
• Trading on a split-adjusted basis began on September 23, 2026, under the ticker symbol IBO with a new CUSIP number 45259L304.
• The filing explains a delay in reporting due to a clerical processing error by the Secretary of State of Nevada, with the file-stamped Amendment received on October 6, 2026.
• The reverse stock split reduced the number of outstanding shares from approximately 107.8 million to approximately 8.6 million.
• No fractional shares were issued; stockholders entitled to fractional shares will receive one full share instead.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral to slightly negative development due to the reverse stock split, which often signals underlying financial challenges, despite the procedural explanation for the late filing.

Positives

• The reverse stock split has been successfully executed and is now effective.
• Trading has commenced on a split-adjusted basis, allowing for potential market adjustments.
• The company has addressed the procedural delay by explaining the clerical error and contacting the NYSE American.

Negatives

• Reverse stock splits are often implemented to increase the stock price, which can be a signal of underlying financial distress or a desire to avoid delisting.
• The delay in filing, though explained by a clerical error, indicates potential administrative inefficiencies.
• The significant reduction in outstanding shares may not fundamentally alter the company's market capitalization or intrinsic value without underlying business improvements.

Risks

• Potential for continued low stock price if the underlying business performance does not improve post-split.
• Negative market perception associated with reverse stock splits, which can deter investors.
• Administrative or procedural issues, as evidenced by the delay in receiving the file-stamped amendment.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the execution of the reverse stock split. The primary implication is an adjustment to the share structure.

Management Comments

• The Company is therefore filing this Current Report on Form 8-K now, rather than within four business days of September 23, 2026, and has been in contact with the New York Stock Exchange American regarding this.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common tactic in the biotechnology and smaller-cap sectors to meet exchange listing requirements or improve the stock's appeal to institutional investors. However, they do not inherently improve a company's fundamentals.

Corporate Governance

Stakeholder Impact

• Shareholders: The number of shares held by each shareholder is reduced by a factor of 12.62, with an equivalent increase in the per-share price, assuming no change in market capitalization.
• Creditors: No direct impact mentioned.
• Employees: No direct impact mentioned.
• Customers/Suppliers: No direct impact mentioned.

Next Steps

• Continue trading on the NYSE American on a split-adjusted basis.
• Monitor market reaction to the reverse stock split.

Key Dates

Recommendation

The reverse stock split itself is a procedural change and does not reflect fundamental business performance. While it may address listing requirements or perception, it carries a negative connotation. Without further information on the company's operational performance or strategic initiatives, a 'hold' recommendation is prudent, pending clearer indicators of value creation.

Keywords

Reverse Stock Split, Common Stock, Certificate of Amendment, Nevada Secretary of State, NYSE American, Stockholder Approval, Effective Time, CUSIP Number